Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling)

Glycosylation is one of the most abundant post-translational modifications that occur within the cell. Under normal physiological conditions, O-linked glycosylation of extracellular proteins is critical for both structure and function. During the progression of cancer, however, the expression of aberrant and truncated glycans is commonly observed. Mucins are high molecular weight glycoproteins that contain numerous sites of O-glycosylation within their extracellular domains. Transmembrane mucins also play a functional role in monitoring the surrounding microenvironment and transducing these signals into the cell. In cancer, these mucins often take on an oncogenic role and promote a number of pro-tumorigenic effects, including pro-survival, migratory, and invasive behaviors. Within this review, we highlight both the processes involved in the expression of aberrant glycan structures on mucins, as well as the potential downstream impacts on cellular signaling.

[1]  Maxime Pinard,et al.  MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. , 2011, Gynecologic oncology.

[2]  L. Borsig,et al.  Altered Tumor-Cell Glycosylation Promotes Metastasis , 2014, Front. Oncol..

[3]  R. Hughey,et al.  MUC1 Membrane Trafficking Is Modulated by Multiple Interactions* , 2004, Journal of Biological Chemistry.

[4]  J. Rhodes,et al.  Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumour cell homotypic aggregation and prevents anoikis , 2010, Molecular Cancer.

[5]  M. Hollingsworth,et al.  Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. , 2010, Cancer research.

[6]  Laura A. Sullivan,et al.  Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer , 2007, Cell.

[7]  R. Cummings,et al.  Cloning and Expression of Human Core 1 β1,3-Galactosyltransferase* , 2002, The Journal of Biological Chemistry.

[8]  K. Carraway,et al.  O‐glycosylation pathway for mucin‐type glycoproteins , 1989, BioEssays : news and reviews in molecular, cellular and developmental biology.

[9]  S. Cascio,et al.  Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migration , 2013, Oncotarget.

[10]  M. Hollingsworth,et al.  MUC1 regulates cyclin D1 gene expression through p120 catenin and β-catenin , 2014, Oncogenesis.

[11]  Xiaofeng Yu,et al.  Aberrant Cosmc genes result in Tn antigen expression in human colorectal carcinoma cell line HT-29. , 2015, International journal of clinical and experimental pathology.

[12]  M. Hollingsworth,et al.  Overexpression of MUC1 reconfigures the binding properties of tumor cells , 2001, International journal of cancer.

[13]  D. Kufe,et al.  Protein Kinase C δ Regulates Function of the DF3/MUC1 Carcinoma Antigen in β-Catenin Signaling* , 2002, The Journal of Biological Chemistry.

[14]  Jian Yu,et al.  Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma , 2011, PloS one.

[15]  I. Gipson,et al.  Epithelial mucins of the ocular surface: structure, biosynthesis and function. , 2001, Experimental eye research.

[16]  Kunling Xie,et al.  The role of the AMOP domain in MUC4/Y-promoted tumour angiogenesis and metastasis in pancreatic cancer , 2016, Journal of Experimental & Clinical Cancer Research.

[17]  Sandra J. Gendler MUC1, The Renaissance Molecule , 2001, Journal of Mammary Gland Biology and Neoplasia.

[18]  Lynette M. Smith,et al.  Mucins and associated glycan signatures in colon adenoma-carcinoma sequence: Prospective pathological implication(s) for early diagnosis of colon cancer. , 2016, Cancer letters.

[19]  Judy M. Anderson,et al.  Pathobiological Implications of MUC16 Expression in Pancreatic Cancer , 2011, PloS one.

[20]  T. Owczarek,et al.  MUC1 in human and murine mammary carcinoma cells decreases the expression of core 2 β1,6-N-acetylglucosaminyltransferase and β-galactoside α2,3-sialyltransferase. , 2012, Glycobiology.

[21]  E. Bennett,et al.  A family of UDP-GalNAc: polypeptide N-acetylgalactosaminyl-transferases control the initiation of mucin-type O-linked glycosylation. , 1996, Glycobiology.

[22]  D. Kufe,et al.  Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16. , 2006, Gene.

[23]  Nicolle H. Packer,et al.  Mucin‐type O‐glycosylation – putting the pieces together , 2010, The FEBS journal.

[24]  Lynette M. Smith,et al.  Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125) , 2006, Modern Pathology.

[25]  Xiaolong Wei,et al.  Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. , 2005, Cancer cell.

[26]  B. Xia,et al.  Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc (Cancer Research (2008) 68, (1636-1646)) , 2008 .

[27]  M. Stack,et al.  Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium , 2014, Biological chemistry.

[28]  J. Ladbury,et al.  Identification of a Novel Proline-Arginine Motif Involved in CIN85-dependent Clustering of Cbl and Down-regulation of Epidermal Growth Factor Receptors* , 2003, Journal of Biological Chemistry.

[29]  N. Schultz,et al.  Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion , 2015, PloS one.

[30]  T. Okada,et al.  Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Peter-Katalinic,et al.  High Density O-Glycosylation on Tandem Repeat Peptide from Secretory MUC1 of T47D Breast Cancer Cells* , 1999, The Journal of Biological Chemistry.

[32]  F. Hanisch,et al.  O-Glycosylation of the Mucin Type , 2001, Biological chemistry.

[33]  O. Weisz,et al.  Recycling of MUC1 Is Dependent on Its Palmitoylation* , 2006, Journal of Biological Chemistry.

[34]  I. Brockhausen,et al.  Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. , 1995, European journal of biochemistry.

[35]  S. Batra,et al.  Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy. , 2011, Biochimica et biophysica acta.

[36]  J. Olsen,et al.  Immature truncated O-glycophenotype of cancer directly induces oncogenic features , 2014, Proceedings of the National Academy of Sciences.

[37]  Y. Kooyk,et al.  Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45 , 2006, Nature Immunology.

[38]  S. Hsu,et al.  C2GnT-M is downregulated in colorectal cancer and its re-expression causes growth inhibition of colon cancer cells , 2006, Oncogene.

[39]  J. Gonzalez-Bosquet,et al.  MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress , 2014, Molecular Cancer.

[40]  I. van Seuningen,et al.  The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways. , 2015, Biochemical and biophysical research communications.

[41]  M. Hollingsworth,et al.  Control of O-Glycan Branch Formation , 1999, The Journal of Biological Chemistry.

[42]  S. Batra,et al.  Structure, evolution, and biology of the MUC4 mucin , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  Subodh M. Lele,et al.  MUC4 Overexpression Augments Cell Migration and Metastasis through EGFR Family Proteins in Triple Negative Breast Cancer Cells , 2013, PloS one.

[44]  J. Meza,et al.  MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. , 2008, Cancer research.

[45]  M. Oka,et al.  Increased expression of MUC1 in advanced pancreatic cancer , 2003, Journal of Gastroenterology.

[46]  S. Batra,et al.  Genomic organization of MUC4 mucin gene. Towards the characterization of splice variants. , 2002, European journal of biochemistry.

[47]  S. Batra,et al.  MUC16: molecular analysis and its functional implications in benign and malignant conditions , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  D. Kufe,et al.  Interaction of Glycogen Synthase Kinase 3β with the DF3/MUC1 Carcinoma-Associated Antigen and β-Catenin , 1998, Molecular and Cellular Biology.

[49]  S. Batra,et al.  Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells , 2015, Oncotarget.

[50]  S. Batra,et al.  Regulation of mucin expression: mechanistic aspects and implications for cancer and inflammatory diseases. , 2006, Biochimica et biophysica acta.

[51]  P. Singh,et al.  The reactive tumor microenvironment: MUC1 signaling directly reprograms transcription of CTGF , 2010, Oncogene.

[52]  S. Gendler,et al.  Structure and function of the cell surface (tethered) mucins. , 2008, Annual review of physiology.

[53]  Denny G. A. Johansson,et al.  Autoproteolysis coupled to protein folding in the SEA domain of the membrane-bound MUC1 mucin , 2006, Nature Structural &Molecular Biology.

[54]  A. Gammerman,et al.  Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer , 2013, British Journal of Cancer.

[55]  C. Lombardo,et al.  Structure, Function and Gene Expression of Epithelial Mucins , 1997, Tumori.

[56]  C. Rancourt,et al.  MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells , 2010, Molecular Cancer.

[57]  D. Kufe MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches , 2013, Oncogene.

[58]  K. Shigemasa,et al.  The CA 125 Gene: A Newly Discovered Extension of the Glycosylated N-Terminal Domain Doubles the Size of This Extracellular Superstructure , 2002, Tumor Biology.

[59]  J. Hirabayashi,et al.  Galectin-3 Interaction with Thomsen-Friedenreich Disaccharide on Cancer-associated MUC1 Causes Increased Cancer Cell Endothelial Adhesion* , 2007, Journal of Biological Chemistry.

[60]  J. Sheehan,et al.  Mucous glycoproteins: a gel of a problem. , 1985, Essays in biochemistry.

[61]  Michael A. Hollingsworth,et al.  Mucins in cancer: protection and control of the cell surface , 2004, Nature Reviews Cancer.

[62]  B. Yin,et al.  Molecular Cloning of the CA125 Ovarian Cancer Antigen , 2001, The Journal of Biological Chemistry.

[63]  A. Moore,et al.  Expression of underglycosylated MUC1 antigen in cancerous and adjacent normal breast tissues. , 2013, Clinical breast cancer.

[64]  D. Kufe Functional targeting of the MUC1 oncogene in human cancers , 2009, Cancer biology & therapy.

[65]  F. Bard,et al.  Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes , 2010, The Journal of cell biology.

[66]  R. Cummings,et al.  A unique molecular chaperone Cosmc required for activity of the mammalian core 1 β3-galactosyltransferase , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[67]  C. Rancourt,et al.  MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling. , 2015, American journal of cancer research.

[68]  M. Hollingsworth,et al.  The role of the SEA (sea urchin sperm protein, enterokinase and agrin) module in cleavage of membrane‐tethered mucins , 2005, The FEBS journal.

[69]  R. Cummings,et al.  Regulation of protein O-glycosylation by the endoplasmic reticulum–localized molecular chaperone Cosmc , 2008, The Journal of cell biology.

[70]  D. Kufe,et al.  The Human DF3/MUC1 carcinoma-associated antigen signals nuclear localization of the catenin p120(ctn). , 2001, Biochemical and biophysical research communications.

[71]  K. Pienta,et al.  Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking , 2009, Proceedings of the National Academy of Sciences.

[72]  Lawrence A Tabak,et al.  Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. , 2012, Glycobiology.

[73]  H. Nakada,et al.  CA125/MUC16 interacts with Src family kinases, and over-expression of its C-terminal fragment in human epithelial cancer cells reduces cell-cell adhesion. , 2013, European journal of cell biology.

[74]  H. Inoue,et al.  Expression of α-1,3-Fucosyltransferase Type IV and VII Genes Is Related to Poor Prognosis in Lung Cancer , 1996 .

[75]  Henrik Clausen,et al.  Mucin-type O-glycosylation and its potential use in drug and vaccine development. , 2008, Biochimica et biophysica acta.

[76]  C. Rancourt,et al.  Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells , 2011, British Journal of Cancer.

[77]  T. Terada An immunohistochemical study of primary signet-ring cell carcinoma of the stomach and colorectum: II. Expression of MUC1, MUC2, MUC5AC, and MUC6 in normal mucosa and in 42 cases. , 2013, International journal of clinical and experimental pathology.

[78]  G. Springer T and Tn, general carcinoma autoantigens. , 1984, Science.

[79]  Chiun-Sheng Huang,et al.  Up-regulation of C1GALT1 promotes breast cancer cell growth through MUC1-C signaling pathway , 2015, Oncotarget.

[80]  D. Kufe,et al.  Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. , 1995, Cancer research.

[81]  S. Hakomori,et al.  Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. , 1985, Cancer research.

[82]  R. Cummings,et al.  The Transmembrane Domain of the Molecular Chaperone Cosmc Directs Its Localization to the Endoplasmic Reticulum* , 2011, The Journal of Biological Chemistry.

[83]  M. Hollingsworth,et al.  Identification of FRA-1 as a novel player in pancreatic cancer in cooperation with a MUC1: ERK signaling axis , 2016, Oncotarget.

[84]  I. Gipson,et al.  Suppression of Toll-like Receptor-Mediated Innate Immune Responses at the Ocular Surface by the Membrane-associated Mucins MUC1 and MUC16 , 2014, Mucosal Immunology.

[85]  H. Kai,et al.  Phosphoinositide 3-kinase is activated by MUC1 but not responsible for MUC1-induced suppression of Toll-like receptor 5 signaling. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[86]  Kwok-Kin Wong,et al.  Targeting the Oncogenic MUC1-C Protein Inhibits Mutant EGFR-Mediated Signaling and Survival in Non–Small Cell Lung Cancer Cells , 2014, Clinical Cancer Research.

[87]  S. Batra,et al.  Current status of mucins in the diagnosis and therapy of cancer , 2009, BioFactors.

[88]  P. Singh,et al.  Cell surface-associated mucins in signal transduction. , 2006, Trends in cell biology.

[89]  B. Yin,et al.  Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene , 2002, International journal of cancer.

[90]  Michael Hust,et al.  Expression of Recombinant Antibodies , 2013, Front. Immunol..

[91]  Y. Takeshima,et al.  Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. , 2004, American journal of clinical pathology.

[92]  T. O'brien,et al.  The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences , 2001, Tumor Biology.

[93]  K. Carraway,et al.  The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms. , 2009, Cancer research.

[94]  J. Epstein,et al.  MUC2 expression in primary mucinous and nonmucinous adenocarcinoma of the prostate: an analysis of 50 cases on radical prostatectomy , 2008, Modern Pathology.

[95]  S. Batra,et al.  MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells , 2012, Oncogene.

[96]  I. Ellis,et al.  Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer , 2005, Modern Pathology.

[97]  Christoph Wagener,et al.  COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer , 2015, Molecular Cancer.

[98]  M. King,et al.  Three to Tango: MUC1 as a Ligand for Both E-Selectin and ICAM-1 in the Breast Cancer Metastatic Cascade , 2012, Front. Oncol..

[99]  E. Cooper,et al.  An evaluation of DUPAN-2 in pancreatic cancer and gastrointestinal disease. , 1990, British Journal of Cancer.

[100]  G. Meijer,et al.  The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma , 2007, Cancer Immunology, Immunotherapy.

[101]  C. A. Carraway,et al.  Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27kip, but does not activate mitogen-activated kinase or protein kinaseB/Akt pathways , 2002, Oncogene.

[102]  S. Batra,et al.  Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifying Golgi/post-Golgi compartments , 2015, Scientific Reports.

[103]  G. Apodaca,et al.  Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state. , 2000, Molecular biology of the cell.

[104]  Hongyan Yuan,et al.  Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21WAF1 pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells , 2015, Oncotarget.

[105]  J. Isola,et al.  Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. , 2005, Cancer research.

[106]  R. Gupta,et al.  Subunit structure of porcine submaxillary mucin. , 1989, Biochemistry.

[107]  P. Cheng,et al.  Mucin O-glycan branching enzymes: structure, function, and gene regulation. , 2011, Advances in experimental medicine and biology.

[108]  Henrik Clausen,et al.  Location, location, location: new insights into O-GalNAc protein glycosylation. , 2011, Trends in cell biology.

[109]  Alexandria P. Cogdill,et al.  Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. , 2016, Immunity.

[110]  P. Schlag,et al.  Overexpression of sialyltransferase CMP-sialic acid:Galbeta1,3GalNAc-R alpha6-Sialyltransferase is related to poor patient survival in human colorectal carcinomas. , 2001, Cancer research.

[111]  G. Springer Tn epitope (N-acetyl-D-galactosamine alpha-O-serine/threonine) density in primary breast carcinoma: a functional predictor of aggressiveness. , 1989, Molecular immunology.

[112]  S. Gendler,et al.  Regulation of mucin genes in chronic inflammatory airway diseases. , 2006, American journal of respiratory cell and molecular biology.

[113]  S. Gendler,et al.  Transgenic MUC1 Interacts with Epidermal Growth Factor Receptor and Correlates with Mitogen-activated Protein Kinase Activation in the Mouse Mammary Gland* , 2001, The Journal of Biological Chemistry.

[114]  J. Rhodes,et al.  Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. , 2009, Cancer research.

[115]  T. Irimura,et al.  Tumor-associated Tn-MUC1 glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. , 2007, Cancer research.

[116]  D. Zander,et al.  MUC4 expression in non-small cell lung carcinomas: relationship to tumor histology and patient survival. , 2007, Archives of pathology & laboratory medicine.

[117]  H. Friess,et al.  Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[118]  M. Hollingsworth,et al.  Expression of core 3 synthase in human pancreatic cancer cells suppresses tumor growth and metastasis , 2013, International journal of cancer.

[119]  S. Kawa,et al.  Clinical evaluation of pancreatic cancer-associated mucin expressing CA19-9, CA50, Span-1, sialyl SSEA-1, and Dupan-2. , 1992, Scandinavian journal of gastroenterology.

[120]  M. Hollingsworth,et al.  Interactions between MUC1 and p120 catenin regulate dynamic features of cell adhesion, motility, and metastasis. , 2014, Cancer research.

[121]  Hongyan Yuan,et al.  Mucin1 promotes the migration and invasion of hepatocellular carcinoma cells via JNK-mediated phosphorylation of Smad2 at the C-terminal and linker regions , 2015, Oncotarget.

[122]  J. Taylor‐Papadimitriou,et al.  The Breast Cancer-Associated Glycoforms of MUC1, MUC1-Tn and sialyl-Tn, Are Expressed in COSMC Wild-Type Cells and Bind the C-Type Lectin MGL , 2015, PloS one.

[123]  Jane L Meza,et al.  MUC4 Mucin Potentiates Pancreatic Tumor Cell Proliferation, Survival, and Invasive Properties and Interferes with Its Interaction to Extracellular Matrix Proteins , 2007, Molecular Cancer Research.

[124]  D. Kufe,et al.  The c-Src Tyrosine Kinase Regulates Signaling of the Human DF3/MUC1 Carcinoma-associated Antigen with GSK3β and β-Catenin* , 2001, The Journal of Biological Chemistry.

[125]  Masanobu Komatsu,et al.  Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor , 2001, Oncogene.

[126]  P. Schwartz,et al.  Circulating tumor markers in the monitoring of gynecologic malignancies , 1987, Cancer.

[127]  G. Rutteman,et al.  Sialylation regulates galectin-3/ligand interplay during mammary tumour progression--a case of targeted uncloaking. , 2011, The International journal of developmental biology.

[128]  Jing-Jing Zhang,et al.  MUC4-induced nuclear translocation of β-catenin: a novel mechanism for growth, metastasis and angiogenesis in pancreatic cancer. , 2014, Cancer letters.

[129]  J. D. Capra,et al.  High-level production of a functional immunoglobulin heterodimer in a baculovirus expression system. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[130]  P. De Camilli,et al.  CIN85 associates with multiple effectors controlling intracellular trafficking of epidermal growth factor receptors. , 2004, Molecular biology of the cell.

[131]  L. Coupland,et al.  Platelets, selectins, and the control of tumor metastasis. , 2014, Seminars in oncology.

[132]  S. Batra,et al.  MUC4 stabilizes HER2 expression and maintains the cancer stem cell population in ovarian cancer cells , 2011, Journal of ovarian research.

[133]  Timothy J. Yeatman,et al.  A renaissance for SRC , 2004, Nature Reviews Cancer.

[134]  Ping Li,et al.  Loss of Core 1-derived O-Glycans Decreases Breast Cancer Development in Mice* , 2015, The Journal of Biological Chemistry.

[135]  H. Nakanishi,et al.  Molecular Cloning and Characterization of a Novel UDP-GlcNAc:GalNAc-peptide β1,3-N-Acetylglucosaminyltransferase (β3Gn-T6), an Enzyme Synthesizing the Core 3 Structure of O-Glycans* , 2002, The Journal of Biological Chemistry.

[136]  Lynette M. Smith,et al.  Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells , 2015, Oncotarget.

[137]  M. Fukuda,et al.  Expression cloning of a cDNA encoding UDP-GlcNAc:Gal beta 1-3-GalNAc-R (GlcNAc to GalNAc) beta 1-6GlcNAc transferase by gene transfer into CHO cells expressing polyoma large tumor antigen. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[138]  S. Batra,et al.  Role of MUC4-NIDO domain in the MUC4-mediated metastasis of pancreatic cancer cells , 2011, Oncogene.

[139]  Judy M. Anderson,et al.  Aberrant Expression of Mucin Core Proteins and O-Linked Glycans Associated with Progression of Pancreatic Cancer , 2013, Clinical Cancer Research.

[140]  P. Singh,et al.  Phosphorylation of MUC1 by Met Modulates Interaction with p53 and MMP1 Expression* , 2008, Journal of Biological Chemistry.

[141]  R. Cummings,et al.  Epigenetic Silencing of the Chaperone Cosmc in Human Leukocytes Expressing Tn Antigen , 2022 .

[142]  G. Huet,et al.  Galectin-3 regulates MUC1 and EGFR cellular distribution and EGFR downstream pathways in pancreatic cancer cells , 2011, Oncogene.

[143]  S. Batra,et al.  A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-β in pancreatic carcinogenesis , 2004, Oncogene.

[144]  B. Xia,et al.  Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. , 2008, Cancer research.

[145]  Matthew R. Dallas,et al.  Mucin 16 is a functional selectin ligand on pancreatic cancer cells , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[146]  R. Hill,et al.  Porcine submaxillary gland apomucin contains tandemly repeated, identical sequences of 81 residues. , 1988, The Journal of biological chemistry.

[147]  N. Smorodinsky,et al.  The MUC1 SEA Module Is a Self-cleaving Domain* , 2005, Journal of Biological Chemistry.

[148]  D. Meerzaman,et al.  Involvement of the MAP kinase ERK2 in MUC1 mucin signaling. , 2001, American journal of physiology. Lung cellular and molecular physiology.

[149]  Sangeeta Bafna,et al.  Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas , 2006, The Prostate.

[150]  M. Pasumarthy,et al.  Site-specific Core 1 O-Glycosylation Pattern of the Porcine Submaxillary Gland Mucin Tandem Repeat , 1998, The Journal of Biological Chemistry.

[151]  B. Pockaj,et al.  Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes , 2016, Biomolecules.

[152]  M. McGuckin,et al.  Structure and function of the polymeric mucins in airways mucus. , 2008, Annual review of physiology.

[153]  J. Jiménez-Barbero,et al.  Thermodynamic Switch in Binding of Adhesion/Growth Regulatory Human Galectin-3 to Tumor-Associated TF Antigen (CD176) and MUC1 Glycopeptides , 2015, Biochemistry.

[154]  H. Wandall,et al.  Glycan Elongation Beyond the Mucin Associated Tn Antigen Protects Tumor Cells from Immune-Mediated Killing , 2013, PloS one.

[155]  Benjamin G. Bitler,et al.  MUC1 regulates nuclear localization and function of the epidermal growth factor receptor , 2010, Journal of Cell Science.

[156]  S. Batra,et al.  MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells , 2008, British Journal of Cancer.

[157]  Ronald J Moore,et al.  Ischemia in Tumors Induces Early and Sustained Phosphorylation Changes in Stress Kinase Pathways but Does Not Affect Global Protein Levels* , 2014, Molecular & Cellular Proteomics.

[158]  S. Batra,et al.  Mucin Expression in Endoscopic Ultrasound-Guided Fine-Needle Aspiration Specimens Is a Useful Prognostic Factor in Pancreatic Ductal Adenocarcinoma , 2015, Pancreas.